ESR1 and breast cancer: A differential PGRMC1 phosphorylation status was shown between estrogen receptor-positive (ER+) and negative (ER-) breast cancers (BC) [190], an indication that PGRMC1 may be involved in the clinical differences between tumors with distinct ER statuses, in a phosphorylation-dependent manner.